Related Experiment Videos
Ibalizumab
Robert L Bettiker1, David E Koren2, Jeffrey M Jacobson1,3,4
1Department of Medicine.
Current Opinion in HIV and AIDS
|May 11, 2018
Summary
Ibalizumab, a new HIV-1 treatment, effectively reduces viral load in patients with multidrug resistance. This parenteral CD4 post-attachment inhibitor shows promise as a safe and effective option for difficult-to-treat HIV-1 infections.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Multiclass resistant HIV-1 necessitates novel antiretroviral agents.
- Ibalizumab offers a unique mechanism of action as a parenteral CD4 post-attachment inhibitor.
Purpose of the Study:
- To review the efficacy and safety of ibalizumab in treating HIV-1.
- To highlight ibalizumab's role in combination antiretroviral therapy for resistant HIV-1.
Main Methods:
- Phase III clinical trial involving HIV-infected participants with multiclass antiretroviral drug resistance.
- Intravenous administration of ibalizumab followed by an optimized background antiretroviral regimen.
Main Results:
- 83% of participants achieved >0.5 log decline in plasma HIV-1 RNA at 1 week.
- 43% achieved plasma HIV-1 RNA <50 copies/ml at 24 weeks with combination therapy.
- Ibalizumab demonstrated a favorable safety profile with uncommon, low-grade adverse effects.
Conclusions:
- Ibalizumab is a safe and effective treatment for HIV-1 infection, particularly for multidrug-resistant cases.
- It is approved as Trogarzo for use in combination antiretroviral therapy.
- Ongoing development aims to enhance ibalizumab's pharmacokinetic profile and broaden its activity.